| Literature DB >> 24742493 |
Khaled Nassar1, Swaantje Grisanti2, Aysegul Tura2, Julia Lüke2, Matthias Lüke2, Mahmoud Soliman3, Salvatore Grisanti2.
Abstract
This study evaluates the use of the TGF-β receptor 1 inhibitor LY-364947 (LY) to prevent proliferative vitreoretinopathy (PVR). For the in vitro experiments Human Tenon's Fibroblasts (HTFs) and retinal pigment epithelial (RPE) cells were treated with different concentrations of LY to determine HTF proliferation and RPE transdifferentiation. For in vivo testing 30 rabbits underwent a PVR trauma model. The animals received different concentrations of intravitreally injected LY, with or without vitrectomy. LY treatment reduced HTF proliferation and RPE transdifferentiation in vitro. In vivo intravitreal injection of LY prevented PVR development significantly. This positive effect was also present when LY injection was combined with vitrectomy. Intravitreal injection of LY prevented tractional retinal detachment in 14 out of 15 animals. In conclusion, treatment with the TGF-β receptor 1 inhibitor LY reduces HTF proliferation and RPE transdifferentiation in vitro and prevents proliferative vitreoretinopathy and subsequent tractional retinal detachment in vivo.Entities:
Keywords: LY-364947; TGF-β receptor 1; penetrating eye injury; proliferative vitreoretinopathy; vitrectomy
Mesh：
Substances：
Year: 2014 PMID： 24742493 DOI： 10.1016/j.exer.2014.04.006
Source DB: PubMed Journal: Exp Eye Res ISSN： 0014-4835 Impact factor: 3.770